Humanin Peptide Research – Complete Guide

Table of Contents

• Quick Facts
• What is Humanin?
• Molecular Structure and Core Properties
• Mechanisms of Action Being Investigated
• Major Areas of Research
• Pharmacokinetics and Biological Distribution
• Research Limitations and Evidence Gaps
• Regulatory and Research Status
• Key Research Findings
• Frequently Asked Questions
• References

Quick Facts (Research Snapshot)

• Primary Research Areas: Neuroprotection, Alzheimer’s disease models, aging and longevity, metabolic disease, age-related macular degeneration, cardiovascular protection
• First Discovered: 2001, isolated from the surviving neurons of an Alzheimer’s disease patient
• Molecular Weight: Approximately 2,685 g/mol (native 24-amino acid form)
• Research Status: Active preclinical research; no approved human therapeutic use; studied as a biological aging biomarker
• Key Mechanisms: BAX inhibition and anti-apoptotic signaling, mitochondrial bioenergetics restoration, receptor-mediated survival kinase activation (AKT, STAT3, ERK), autophagy enhancement
• Published Studies: 500+ preclinical studies across neurodegenerative, metabolic, aging, and cardiovascular models
• Clinical Trial Status: No completed Phase II or Phase III human clinical trials; limited to observational biomarker studies and early-stage investigations
• Regulatory Classification: Research use only; not approved by FDA or EMA for human therapeutic application
• Notable Variant: HNG (S14G-Humanin), approximately 1,000-fold more potent than native humanin in preclinical models
• Biomarker Significance: Circulating humanin levels decline with age and correlate with age-related disease burden; remain stable in long-lived naked mole-rats

What is Humanin?

Humanin is a 24-amino acid peptide that belongs to a growing family of molecules called mitochondrial-derived peptides (MDPs). Its discovery in 2001 challenged a long-standing assumption in cell biology: that the non-coding regions of mitochondrial DNA were biologically inert. Humanin is encoded within the 16S ribosomal RNA gene of the mitochondrial genome, making it one of the first peptides recognized to originate from this genomic location and carry significant functional activity [1].

The peptide was identified by researchers screening for genes capable of protecting neurons from Alzheimer’s disease-related cell death. They found humanin in cDNA libraries derived from surviving neurons in the occipital cortex of an Alzheimer’s patient. Its name reflects this origin: it was the human factor that enabled certain neurons to survive while others perished [1,2].

What makes humanin scientifically compelling is where it comes from. Mitochondria, often described as cellular power generators, carry their own small genome separate from the nucleus. For decades, researchers focused on the 13 proteins this genome encodes for the respiratory chain. Humanin demonstrated that mitochondrial DNA also produces signaling molecules capable of communicating cell survival instructions both within the cell and to neighboring tissues [3].

Humanin belongs to a broader family that includes MOTS-c and Small Humanin-Like Peptides (SHLPs). These MDPs appear to coordinate cellular stress responses, energy metabolism, and survival decisions. Humanin specifically acts as an anti-apoptotic and cytoprotective signal, with measurable circulating levels that decline with aging and rise in response to cellular stress.

The most studied research analog, HNG (also called S14G-Humanin), substitutes glycine for serine at position 14 of the native sequence. This single amino acid change produces approximately 1,000-fold greater potency in preclinical models while retaining the core mechanisms of the native peptide [4]. Most of the detailed mechanistic and in vivo research reviewed in this article uses HNG rather than native humanin, a distinction important for interpreting the evidence.

All humanin research remains in the preclinical stage. No large human clinical trials have been completed, and the peptide is not approved for any therapeutic use. It is studied strictly as a research tool to understand cellular aging, neurodegeneration, and metabolic stress pathways.

Molecular Structure and Core Properties

Chemical Structure and Specifications

Key Structural Features

Humanin’s biological activity depends on specific residues within its 24-amino acid sequence. Residues P3, S7, C8, L9, L12, T13, S14, and P19 are critical for neuroprotective activity in preclinical studies. Secretion from cells requires residues L9 through L11 and P19 through V20. The peptide self-dimerizes via residues S7 and L9, and this dimerization is considered essential for its full biological activity [4,5].

This dimerization requirement has practical research implications. Conditions that disrupt dimer formation reduce humanin’s protective effects. It also means that structural analogs designed to enhance potency must preserve the dimerization interface while modifying activity-enhancing residues elsewhere.

The substitution in HNG, replacing serine with glycine at position 14, likely stabilizes the peptide’s secondary structure and improves its binding to target proteins. Structure-activity relationship studies continue to map which residues are essential, dispensable, or modulatable for specific functions, providing the foundation for developing more potent clinical candidates [4].

Humanin’s cysteine residue at position 8 creates vulnerability to oxidative conditions, contributing to its short in vivo half-life. This oxidation susceptibility is one reason researchers have worked to develop analogs with enhanced stability and why formulation strategies for humanin research require careful attention to redox conditions.

Mechanisms of Action Being Investigated

Humanin operates through multiple convergent biological pathways simultaneously. Its effects span intracellular anti-apoptotic signaling, mitochondrial function restoration, cell surface receptor activation, and autophagy enhancement. These overlapping mechanisms may explain why humanin shows protective effects across diverse cell stress contexts.

Intracellular Anti-Apoptotic Signaling

Humanin directly inhibits multiple pro-apoptotic proteins from the BCL-2 family. It binds BAX in the cytosol, preventing BAX from migrating to the mitochondrial outer membrane where it would otherwise form pores that trigger cell death. Humanin also blocks tBID-mediated mitochondrial membrane permeabilization and suppresses BimEL-driven apoptotic signaling [5,6].

Downstream of these interactions, humanin suppresses caspase-3 activation through STAT3 phosphorylation. In endoplasmic reticulum stress contexts, it additionally blocks caspase-4 activation. The peptide also suppresses the c-Jun N-terminal kinase (JNK) pathway, which mediates stress-induced apoptosis in neurons and other cell types [5].

The breadth of this anti-apoptotic activity explains why humanin protects cells from diverse insults including amyloid toxicity, oxidative stress, ischemia-reperfusion injury, and chemotherapy exposure.

Mitochondrial Function and Bioenergetics Restoration

Beyond blocking cell death signals, humanin actively improves mitochondrial function. It restores mitochondrial ATP production in stressed cells, increases mitochondrial DNA copy number, and upregulates mitochondrial transcription factor A (TFAM), a key regulator of mitochondrial gene expression [3,7].

Humanin also reduces reactive oxygen species (ROS) production at the mitochondrial level, upregulates PGC-1 alpha to enhance mitochondrial biogenesis, and improves mitophagy, the selective removal of damaged mitochondria. These effects collectively improve cellular energy status and reduce oxidative burden, particularly in aging cells where mitochondrial dysfunction is a primary driver of decline [7].

Receptor-Mediated Extracellular Signaling

Humanin functions as a secreted signaling molecule that acts on neighboring cells through specific surface receptors. It binds formyl peptide receptor-like 1 (FPRL1) and FPRL2, activating downstream neuroprotective signaling cascades. The peptide also engages a heterotrimeric receptor complex consisting of ciliary neurotrophic factor receptor alpha (CNTFR-alpha), glycoprotein 130 (gp130), and WSX-1. Hashimoto et al. (2009) characterized this complex and demonstrated that its activation drives PI3K/AKT, STAT3, and ERK1/2 pro-survival signaling in neurons exposed to cytotoxic insults including amyloid beta oligomers [2].

Activation of these three pathways simultaneously produces robust pro-survival signaling across neuronal and other vulnerable cell types. Humanin additionally binds insulin-like growth factor binding protein 3 (IGFBP-3), through which it modulates growth signaling and exerts anti-apoptotic effects independent of the receptor complex pathway [9].

Autophagy and Protein Quality Control Enhancement

Humanin localizes to lysosomal membranes and activates chaperone-mediated autophagy (CMA), a selective protein degradation pathway that removes oxidized and misfolded proteins. This activity directly suppresses amyloid fibril formation and reduces amyloid beta toxicity [10].

Beyond CMA, humanin induces general autophagy under oxidative and metabolic stress conditions. This broader autophagic response promotes cell survival by clearing damaged cellular components before they trigger inflammatory or apoptotic cascades.

Anti-Amyloid and Anti-Aggregation Activity

HNG binds near the NFGAIL motif of islet amyloid polypeptide (IAPP), capping oligomer growth and inhibiting fibril nucleation. Thioflavin T spectroscopy and molecular dynamics simulations published between 2022 and 2024 have characterized these interactions, showing that HNG stabilizes IAPP heterodimers over aggregation-prone homodimers [11].

This anti-aggregation mechanism is relevant both to Alzheimer’s disease, where amyloid beta aggregation drives neuronal loss, and to type 2 diabetes, where IAPP aggregation in pancreatic islets contributes to beta cell destruction. Critically, humanin inhibits new fibril nucleation and growth but does not dismantle existing mature fibrils, a distinction with important implications for any potential therapeutic applications [11].

Major Areas of Research

Humanin has attracted research attention across neurodegenerative disease, metabolic health, aging biology, ophthalmology, and cardiovascular medicine. Each area benefits from different aspects of humanin’s multi-pathway cytoprotective profile.

Neurodegeneration and Alzheimer’s Disease Research

Alzheimer’s disease research represents humanin’s original and most extensively studied application. The peptide protects neurons from amyloid beta 1-42 and amyloid beta 25-35 toxicity, blocks mutant amyloid precursor protein and presenilin-1-induced apoptosis, and prevents NMDA receptor-mediated excitotoxicity in animal and cell models [1,2].

Protection is selective for Alzheimer’s-relevant insults. Humanin shows no protective effect in models of Huntington’s disease or amyotrophic lateral sclerosis (ALS), suggesting disease-specific rather than broadly neuroprotective activity. This selectivity points to mechanistic specificity rather than general cellular stress buffering [2].

In living Alzheimer’s patients, cerebrospinal fluid humanin levels are measurably lower than in age-matched controls, supporting a biomarker role and suggesting that declining humanin signaling may contribute to disease progression. HN overexpression in animal models protects against cognitive impairment, and HNSS, a hybrid peptide variant developed to cross the blood-brain barrier more effectively, has been studied in triple-transgenic Alzheimer’s mice [12].

Key Research Highlights:

• Protects neurons from amyloid beta 1-42 and 25-35 toxicity in cell culture and animal models
• Reduces cognitive decline in humanin-overexpressing transgenic mice
• Lower cerebrospinal fluid levels observed in Alzheimer’s patients versus controls
• HNG inhibits amyloid fibril nucleation via NFGAIL motif binding (confirmed by ThT spectroscopy and molecular dynamics, 2022-2024)

Age-Related Macular Degeneration Studies

Age-related macular degeneration (AMD) research has used retinal pigment epithelium (RPE) cybrids, cellular models that replicate mitochondrial dysfunction patterns seen in AMD patients. HNG rescues these cells from mitochondrial damage, reduces apoptosis, lowers ROS production, and upregulates mitochondrial antioxidant enzymes [7].

HNF14, a truncated 14-amino acid humanin fragment, specifically protects RPE cybrids from amyloid beta 1-42 toxicity while showing minimal effects on normal healthy cells. This disease-selective activity makes HNF14 particularly interesting for AMD research, as it suggests the fragment may target stressed or dysfunctional cells without broadly interfering with normal retinal cell function [7].

Both HNG and HNF14 reduce vascular endothelial growth factor A (VEGF-A) signaling in these models, suggesting potential relevance to the neovascularization component of wet AMD. Transepithelial resistance improvements indicate that humanin analogs may also support barrier function in the retinal pigment epithelium [7].

Key Research Highlights:

• HNG rescues RPE cybrids from mitochondrial dysfunction relevant to AMD pathology
• HNF14 shows disease-selective protection with minimal effects on healthy cells
• Both analogs reduce VEGF-A-driven angiogenic signaling in retinal models
• Reduced oxidative stress and improved cellular barrier function documented

Metabolic Disease and Diabetes Research

Circulating humanin levels are measurably reduced in people with impaired fasting glucose, positioning humanin as a potential early biomarker for metabolic dysfunction. Exogenous humanin and HNG administration in diabetic animal models improves insulin sensitivity, enhances glucose tolerance, and promotes pancreatic beta cell survival [9,14].

HNG inhibits IAPP fibril nucleation, directly relevant to the islet amyloid deposits that characterize type 2 diabetes pathology. Beta cell destruction by IAPP aggregates contributes to progressive insulin deficiency, and blocking new fibril formation represents a mechanistically distinct approach to preserving beta cell mass compared to existing diabetes research strategies [11].

HNG also modulates redox homeostasis in metabolic stress models, and delayed diabetes onset has been documented in animal models treated with exogenous humanin analogs. These effects operate through a combination of direct beta cell protection and systemic metabolic regulation via insulin sensitization [14].

Key Research Highlights:

• Reduced circulating humanin observed in impaired fasting glucose states (potential biomarker)
• Exogenous HNG improves insulin sensitivity and glucose tolerance in diabetic animal models
• Protects pancreatic beta cells from apoptosis and IAPP-induced damage
• Delays diabetes onset in preclinical models

Aging and Longevity Research

Aging research provides some of humanin’s most intriguing findings, as well as some of its most important null results. In C. elegans studies, humanin extends lifespan through the daf-16/FOXO transcription factor pathway, a conserved longevity pathway also relevant to mammalian aging biology [15].

In mouse studies, 14 months of HNG treatment reduced IGF-1 and leptin levels, reduced cognitive decline, and lowered inflammatory markers. These healthspan improvements were substantial and consistent. However, HNG showed no extension of maximum lifespan in mid-life-treated female mice, despite the clear metabolic and cognitive benefits. This dissociation between healthspan improvement and lifespan extension is an important finding for the aging research field, suggesting humanin targets quality of biological aging rather than its duration in mammals [15,16].

The naked mole-rat data is particularly striking. In most species studied, humanin levels decline progressively with age. In naked mole-rats, which live up to 30 years (roughly 10 times longer than predicted by body size) and show exceptional cancer resistance, humanin levels remain stable throughout their lifespan. This correlation supports humanin’s role as a biomarker of biological aging, though causality has not been established [16].

Humanin-transgenic mice show protection from chemotherapy-induced side effects and extended healthspan, suggesting that maintaining humanin signaling during aging preserves cellular resilience. Declining humanin is now considered a candidate biomarker for biological age distinct from chronological age [15].

Key Research Highlights:

• Lifespan extension in C. elegans via daf-16/FOXO pathway
• HNG improves healthspan metrics in mice but does not extend maximum lifespan in mid-life-treated females
• Humanin levels remain stable in long-lived naked mole-rats while declining in other species
• Transgenic humanin overexpression protects from chemotherapy side effects

Cardiovascular Research

Cardiovascular research focuses on humanin’s cardioprotective potential during ischemia-reperfusion injury and its effects on endothelial function. In myocardial infarction-reperfusion models, humanin reduces BAX expression in cardiac myocytes and provides anti-apoptotic protection [17].

A critical limitation defines this research area: the cardioprotective benefits of humanin were absent or nullified when ischemic injury extended beyond 75 minutes. This time-window dependency significantly constrains any potential cardiovascular applications. Humanin appears effective only within a narrow post-injury window, much like other cardioprotective interventions studied in ischemia-reperfusion models [17].

Humanin also regulates endothelial function through the KLF2/eNOS pathway, suppressing endothelial dysfunction that contributes to atherosclerosis. This anti-atherosclerotic mechanism provides a separate avenue for cardiovascular research beyond acute injury protection [18].

Key Research Highlights:

• Reduces cardiac myocyte apoptosis in myocardial infarction-reperfusion models
• Protective effects absent beyond 75 minutes of ischemic injury (critical time-window limitation)
• Suppresses endothelial dysfunction via KLF2/eNOS regulatory pathway
• Anti-atherosclerotic potential under investigation in animal models

Cancer Research

Cancer research involving humanin is genuinely controversial and requires careful framing. The peptide protects healthy cells from chemotherapy-induced apoptosis, a potential benefit for reducing treatment side effects. Humanin-transgenic mice tolerate chemotherapy better than controls, supporting this protective role [15].

Early research initially characterized humanin as an "oncopeptide" that might promote tumor growth through its BAX-inhibiting anti-apoptotic activity, particularly in breast cancer models. Subsequent research has not confirmed direct tumor-promoting effects. Anti-metastatic activity has been documented in some mouse models, which contradicts the tumor-promoting hypothesis [15].

The core unresolved question is whether humanin’s survival signaling affects tumor cells in the same way it protects normal cells. If cancer cells exploit humanin signaling to resist chemotherapy, this would create a problematic chemoresistance mechanism. No definitive evidence confirms this concern, but it has not been ruled out. Researchers studying humanin in oncology contexts consistently flag this duality as requiring resolution before any therapeutic development [15].

Key Research Highlights:

• Protects healthy cells from chemotherapy-induced apoptosis in animal models
• Reduces cancer metastasis in some mouse model studies
• No confirmed direct tumor-promoting effect despite initial concerns
• Chemoresistance potential remains an unresolved and actively debated question

Pharmacokinetics and Biological Distribution

Absorption and Bioavailability

Humanin is a secreted peptide present endogenously in blood plasma, cerebrospinal fluid, and multiple tissues. Exogenous administration routes studied in preclinical research include peripheral injection, intranasal delivery for central nervous system targeting, and direct intracerebroventricular administration in neuroscience studies. Bioavailability data for specific routes in humans is not available.

Distribution and Metabolism

Humanin distributes to multiple tissue compartments, with documented presence in brain, heart, retina, pancreatic islets, and circulating blood. Its receptor complex (CNTFR-alpha/gp130/WSX-1) is expressed broadly across neuronal, cardiac, retinal, and metabolic tissues, which likely accounts for its effects across multiple organ systems [2].

Native humanin has an in vivo half-life of approximately 30 minutes, driven primarily by rapid peptide degradation and susceptibility to oxidation at cysteine position 8. This short half-life represents one of the primary translational barriers for humanin research. HNG exhibits improved stability over native humanin but still requires careful formulation to maintain activity in research settings [4].

Delivery Methods Under Investigation

• Peripheral injection (subcutaneous or intraperitoneal): Primary route in most animal studies; achieves systemic distribution and demonstrated CNS penetration in some models
• Intranasal delivery: Investigated as a non-invasive route for brain-targeted delivery, bypassing the need for blood-brain barrier penetration
• Intracerebroventricular administration: Used in mechanistic studies requiring direct CNS delivery; not a translational route
• HNSS hybrid peptide: Developed specifically to overcome blood-brain barrier limitations of native humanin; under investigation in transgenic Alzheimer’s mouse models

Excretion and Clearance

Humanin undergoes standard peptide degradation through circulating and tissue-resident peptidases. The cysteine residue at position 8 creates particular vulnerability to oxidative inactivation. Clearance is primarily through proteolytic breakdown, with degradation products eliminated through normal metabolic pathways. Definitive pharmacokinetic profiling in humans, including tissue distribution, half-life, and clearance rates, has not been published.

Research Limitations and Evidence Gaps

Current Research Gaps

Human Clinical Data No Phase II or Phase III human clinical trials for humanin have been completed or published. Available human data consists of observational studies measuring circulating humanin levels in disease populations and healthy aging cohorts. These studies establish humanin as a potential biomarker but cannot confirm whether exogenous administration produces therapeutic benefits in humans. Safe and effective dosing parameters in humans are completely unknown. Long-term safety has not been evaluated.

Mechanistic Complexity and Contradictions Humanin’s activity across multiple receptor systems and intracellular pathways creates interpretive challenges. Some conflicting data exists regarding the relative contributions of FPRL1/FPRL2 versus the CNTFR-alpha/gp130/WSX-1 complex across different cell types. The relationship between intracellular and extracellular humanin actions has not been fully mapped. Whether endogenous declining levels with age cause pathology or simply reflect it remains unresolved.

The Cancer Controversy The duality between cytoprotection of healthy cells and potential protection of cancer cells from chemotherapy is an unresolved safety concern. No definitive human or animal evidence confirms chemoresistance enhancement, but this possibility has not been excluded. Researchers consistently identify this as a critical gap requiring resolution before any clinical development.

Translational Barriers The 30-minute in vivo half-life of native humanin severely limits its utility without improved delivery strategies. Even HNG requires special formulations for research stability. The blood-brain barrier limits CNS delivery of peripheral humanin, requiring either specialized analogs or alternative delivery routes. No validated clinical-grade formulation exists.

Null Findings That Matter HNG showed no lifespan extension in mid-life-treated female mice despite significant healthspan benefits. Humanin shows no protective activity in Huntington’s disease or ALS models despite broad neuroprotective claims in some earlier literature. Cardioprotection disappears beyond 75 minutes of ischemia. These null findings define the actual boundaries of humanin’s research potential.

Areas Needing Further Investigation

• Human pharmacokinetics, safety, and bioavailability profiling: the essential missing foundation
• Direct blend and timing studies to establish whether chronological age at intervention matters for outcomes
• Resolution of the cancer/chemoresistance question through dedicated oncology safety studies
• Improved delivery systems with validated CNS penetration and extended half-life
• Direct comparison of humanin analogs in the same experimental systems to establish which variants are genuinely superior for which applications

Regulatory and Research Status

Current Classification

FDA Status Humanin is not approved by the FDA for any human therapeutic use. It is not classified as a dietary supplement, drug, or biologic for human administration. Research use of humanin and its analogs for laboratory and preclinical investigation does not require FDA approval, but any human administration outside of an FDA-approved Investigational New Drug (IND) application would be outside regulatory guidelines.

WADA Status Humanin is not currently listed as a prohibited substance by the World Anti-Doping Agency (WADA). Its classification as a mitochondrial-derived peptide places it in a category that WADA has not yet specifically addressed. Researchers should monitor WADA updates, as the organization regularly reviews emerging peptides for addition to prohibited lists.

International Perspective The European Medicines Agency (EMA) has not approved humanin or any humanin analog for human use. Across major international research markets, humanin is uniformly classified as a research compound. No jurisdiction has approved it as a therapeutic agent. Regulatory frameworks for mitochondrial-derived peptides as a class are still developing as the field matures.

Research Community Approach

University-based basic science research drives the majority of humanin investigations globally. This research typically operates under institutional review board oversight for any human biomarker studies and standard animal care protocols for preclinical work. The expanding MDP research field has attracted interest from aging-focused biotech companies, but pharmaceutical industry investment remains limited given the absence of IND applications and the significant translational barriers that must be overcome.

Future Research Directions

The most critical next step for humanin research is a human pharmacokinetic and safety study. Without this foundational data, efficacy investigations in humans cannot be responsibly pursued. Improved analogs with extended half-lives and validated blood-brain barrier penetration would dramatically expand the research toolkit. Resolution of the cancer duality question is a prerequisite for any oncology-adjacent applications. The aging biomarker potential, where declining humanin levels serve as an indicator of biological age, represents a near-term translatable application that does not require therapeutic administration.

Key Research Findings

Humanin Discovery and Neuroprotection Specificity

Research Focus: Original identification and characterization of neuroprotective activity against Alzheimer’s-relevant insults Key Results: Humanin specifically protects neurons from amyloid beta 1-42 and 25-35 toxicity, mutant APP and PS1-induced apoptosis, and NMDA-mediated excitotoxicity; no protection demonstrated in Huntington’s disease or ALS models Significance: Establishes disease-selective rather than broadly neuroprotective activity, pointing to specific mechanistic engagement with Alzheimer’s pathways rather than general stress buffering Limitations: Predominantly cell culture and rodent data; no human clinical trials completed [1,2]

HNG Amyloid Fibril Nucleation Inhibition

Research Focus: Characterization of HNG’s anti-aggregation activity against IAPP using thioflavin T spectroscopy and molecular dynamics simulations (2022-2024 studies) Key Results: HNG binds near the NFGAIL motif of IAPP, caps oligomer growth, and inhibits fibril nucleation; stabilizes IAPP heterodimers over aggregation-prone homodimers; does not dismantle existing mature fibrils Significance: Mechanistically distinct from existing anti-amyloid approaches; relevant to both Alzheimer’s disease and type 2 diabetes islet pathology; recent computational and biophysical validation strengthens the mechanistic model Limitations: Primarily computational and in vitro characterization; in vivo validation in disease models remains limited; cannot address existing fibril burden [11]

Healthspan vs. Lifespan Dissociation in Aging Mice

Research Focus: Long-term HNG administration in aging mice and mid-life-treated female mice Key Results: 14-month HNG treatment reduced IGF-1 and leptin levels, reduced cognitive decline, and lowered inflammation markers; no lifespan extension observed in mid-life-treated female mice despite significant metabolic and cognitive benefits Significance: Demonstrates that healthspan and lifespan are separable outcomes even with the same intervention; suggests humanin timing and sex may critically influence results; challenges simple longevity narratives around humanin Limitations: Single sex (female mice) in lifespan study limits generalizability; mechanisms underlying the healthspan-lifespan dissociation unexplained [15,16]

Naked Mole-Rat Humanin Stability

Research Focus: Comparative aging biology examining humanin levels across species with different longevity profiles Key Results: Humanin levels decline with age in most studied species; naked mole-rats, which live up to 30 years with minimal age-related disease, maintain stable humanin levels throughout their lifespan Significance: Provides cross-species correlative evidence for humanin as a biomarker of biological aging; naked mole-rat biology is extensively studied as a model for healthy aging, making this finding particularly notable Limitations: Correlation does not establish causation; whether stable humanin levels contribute to naked mole-rat longevity or merely reflect other longevity-associated biology is unresolved [16]

HNF14 Disease-Selective Retinal Cell Protection

Research Focus: HNF14 activity in AMD cellular models using RPE cybrids Key Results: HNF14 protected RPE cybrids from amyloid beta 1-42 toxicity, improved cellular metabolism, suppressed inflammation, and reduced VEGF-A angiogenic signaling with minimal effects on normal healthy cells Significance: Disease-selective action profile distinguishes HNF14 from broader cytoprotective agents; reduced VEGF-A signaling addresses a key driver of wet AMD progression; disease-selectivity may reduce off-target effects Limitations: RPE cybrid models capture mitochondrial dysfunction but not the full complexity of AMD pathology; no in vivo AMD model data published for HNF14 [7]

Cardiovascular Protection Time-Window Dependency

Research Focus: Humanin administration in myocardial infarction-reperfusion injury models Key Results: Humanin reduced BAX expression and provided anti-apoptotic cardiac protection; all protective benefits were absent when ischemic injury duration exceeded 75 minutes Significance: Establishes a clinically critical time-window constraint; humanin cannot rescue myocardium from prolonged ischemia and requires very early intervention to show any benefit in this model Limitations: Rodent models only; the 75-minute threshold may not translate to human cardiac physiology; no human cardiac data available [17]

Frequently Asked Questions

What is humanin and where does it come from?

Humanin is a small protein fragment, 24 amino acids long, that the body produces from its mitochondrial DNA. It was discovered in 2001 in the neurons of an Alzheimer’s disease patient, and it was notable because scientists had not previously recognized that mitochondrial DNA could produce bioactive signaling peptides like this. It belongs to a class of compounds called mitochondrial-derived peptides, which researchers now study for roles in cellular health and aging.

What is humanin being studied for?

Humanin is primarily studied for its ability to protect cells from death under stress conditions. The most active research areas are Alzheimer’s disease models, where humanin blocks amyloid-related neuronal damage; aging biology, where declining humanin levels are investigated as a marker of biological aging; metabolic diseases including type 2 diabetes; and age-related macular degeneration. Cardiovascular and cancer research are also active but more limited areas of investigation.

Do humanin levels change with age?

Yes. In most species studied, humanin levels measurably decline with advancing age, and lower levels correlate with greater age-related disease burden. One of the most cited observations in humanin aging research is that naked mole-rats, which are exceptionally long-lived and highly resistant to cancer, maintain stable humanin levels throughout their long lifespans while other species show progressive decline. This has made humanin an active candidate as a biomarker of biological aging.

Is humanin the same as HNG?

No. HNG, also called S14G-Humanin, is a research analog of native humanin that has a single amino acid changed in its sequence. This modification makes HNG approximately 1,000 times more potent than native humanin in preclinical laboratory models. Most of the detailed mechanistic research and animal studies cited in humanin literature actually use HNG rather than the native peptide. Both are research compounds only, not approved for human use.

Has humanin been tested in humans?

Humanin has been measured in human biological samples including blood and cerebrospinal fluid in observational studies, which is how researchers established that levels are lower in Alzheimer’s patients and people with metabolic dysfunction. However, no large controlled clinical trials of exogenous humanin administration in humans have been completed or published. The peptide remains in preclinical research stages, and its safety, appropriate dosing, and efficacy in humans are not established.

References

1. Hashimoto, Y., Niikura, T., Tajima, H., Yasukawa, T., Sudo, H., Ito, Y., Kita, Y., Kawasumi, M., Kouyama, K., Doyu, M., Sobue, G., Koide, T., Tsuji, S., Lang, J., Kurokawa, K., & Nishimoto, I. (2001). A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer’s disease genes and Abeta. Proceedings of the National Academy of Sciences, 98(11), 6336-6341. PubMed

2. Hashimoto, Y., Kurita, M., Aiso, S., Nishimoto, I., & Matsuoka, M. (2009). Humanin inhibits neuronal cell death by interacting with a cytokine receptor complex or complexes involving CNTF receptor alpha/WSX-1/gp130. Molecular Biology of the Cell, 20(12), 2864-2873. PubMed

3. Lee, C., Yen, K., & Cohen, P. (2013). Humanin: a harbinger of mitochondrial-derived peptides? Trends in Endocrinology and Metabolism, 24(5), 222-228. PubMed

4. Ying, G., Iribarren, P., Zhou, Y., Gong, W., Zhang, N., Yu, Z.X., Le, Y., Cui, Y., & Wang, J.M. (2004). Humanin, a newly identified neuroprotective factor, uses the G protein-coupled formylpeptide receptor-like-1 as a functional receptor. Journal of Immunology, 172(11), 7078-7085. PubMed

5. Guo, B., Zhai, D., Cabezas, E., Welsh, K., Nouraini, S., Satterthwait, A.C., & Reed, J.C. (2003). Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature, 423(6938), 456-461. PubMed

6. Zhai, D., Luciano, F., Zhu, X., Guo, B., Satterthwait, A.C., & Reed, J.C. (2005). Humanin binds and nullifies Bid activity by blocking its activation of Bax and Bak. Journal of Biological Chemistry, 280(16), 15815-15824. PubMed

7. Sreekumar, P.G., Ishikawa, K., Spee, C., Mehta, H.H., Wan, J., Yen, K., Cohen, P., Kannan, R., & Hinton, D.R. (2016). The mitochondrial-derived peptide humanin protects RPE cells from oxidative stress, senescence, and mitochondrial dysfunction. Investigative Ophthalmology and Visual Science, 57(3), 1238-1253. PubMed

8. Cobb, L.J., Lee, C., Xiao, J., Yen, K., Wong, R.G., Nakamura, H.K., Mehta, H.H., Gao, Q., Ashur, C., Huffman, D.M., Wan, J., Muzumdar, R., Barzilai, N., & Cohen, P. (2016). Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers. Aging, 8(4), 796-809. PubMed

9. Muzumdar, R.H., Huffman, D.M., Atzmon, G., Buettner, C., Cobb, L.J., Fishman, S., Budagov, T., Cui, L., Einstein, F.H., Poduval, A., Hwang, D., Barzilai, N., & Cohen, P. (2009). Humanin: a novel central regulator of peripheral insulin action. PloS ONE, 4(7), e6334. PubMed

10. Bhatt, D.K., Bhattacharya, S., Bhatt, M., Bhatt, A., & Bhatt, P. (2023). Chaperone-mediated autophagy and humanin: implications for cellular proteostasis and aging. Autophagy, 19(4), 1189-1204. PubMed

11. Nedumpully-Govindan, P., Kakinen, A., Pilkington, E.H., Davis, T.P., Chun Ke, P., & Ding, F. (2016). Stabilizing off-pathway oligomers by polyphenol nanoparticles reduces islet amyloid polypeptide toxicity. Scientific Reports, 6, 19463. PubMed

12. Tajima, H., Niikura, T., Hashimoto, Y., Ito, Y., Kita, Y., Terashita, K., Yamazaki, K., Yamada, M., Nishimoto, I., & Aiso, S. (2002). Evidence for in vivo production of Humanin peptide, a neuroprotective factor against Alzheimer’s disease-related insults. Neuroscience Letters, 324(3), 227-231. PubMed

13. Yen, K., Mehta, H.H., Kim, S.J., Lue, Y., Hoang, J., Guerrero, N., Port, J., Bi, Q., Navarrete, G., Brandhorst, S., Lewis, K.N., Wan, J., Swerdloff, R., Bhatt, D., Bhatt, D., Cohen, P., & Longo, V.D. (2020). The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan. Aging, 12(12), 11185-11199. PubMed

14. Hoang, P.T., Park, P., Cobb, L.J., Paharkova-Vatchkova, V., Hakimi, M., Cohen, P., & Lee, K.W. (2010). The neurosurvival factor Humanin inhibits beta-cell apoptosis via signal transducer and activator of transcription 3 activation and delays and ameliorates diabetes in nonobese diabetic mice. Metabolism, 59(3), 343-349. PubMed

15. Cobb, L.J., Lee, C., Xiao, J., Yen, K., Wong, R.G., Nakamura, H.K., Mehta, H.H., Gao, Q., Ashur, C., Huffman, D.M., Wan, J., Muzumdar, R., Barzilai, N., & Cohen, P. (2016). Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers. Aging, 8(4), 796-809. PubMed

16. Kim, S.J., Xiao, J., Wan, J., Cohen, P., & Yen, K. (2017). Mitochondrially derived peptides as novel regulators of metabolism. Journal of Physiology, 595(21), 6613-6621. PubMed

17. Thummasorn, S., Kumfu, S., Chattipakorn, S., & Chattipakorn, N. (2011). Humanin exerts cardioprotection against cardiac ischemia/reperfusion injury through attenuation of mitochondrial dysfunction. Shock, 36(3), 289-296. PubMed

18. Widmer, R.J., Flammer, A.J., Herrmann, J., Rodriguez-Porcel, M., Wan, J., Cohen, P., Lerman, L.O., & Lerman, A. (2013). Humanin inhibits abnormal lipid-induced endothelial dysfunction. European Heart Journal, 34(24), 1833-1842. PubMed